1. How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from January to April 2022:
a. Aflibercept
b. Bevacizumab
c. Brolucizumab
d. Dexamethasone
e. Fluocinolone acetonide
f. Ranibizumab
2. Please provide the number of injections/implants by eye condition for the four-month period from January to April 2022.
Eye Conditions
Wet Age-Related Macular Degeneration wAMD
Diabetic Macular Degeneration DMO
Retinal Vein Occulusion RVO
Treatment
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Fluocinolone acetonide
Ranibizumab
